Platelet glycoprotein IIb/IIIa PlA2/PlA2homozygosity associated with risk of ischemic cardiovascular disease and myocardial infarction in young men The Copenhagen City Heart Study by Bojesen, Stig E. et al.
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OBJECTIVES We tested the hypothesis that platelet glycoprotein (GP) IIb/IIIa PlA2/PlA2 homozygotes or
PlA1/PlA2 heterozygotes versus PlA1/PlA1 noncarriers have increased risk of ischemic
cardiovascular disease and myocardial infarction (MI), stratified for age and gender.
BACKGROUND The GP IIb/IIIa PlA1/PlA2 polymorphism influences aggregation of platelets; however, an
association between ischemic cardiovascular disease and heterozygosity remains controversial,
and association with homozygosity is largely unexplored.
METHODS We genotyped the participants of the Copenhagen City Heart Study, a prospective
cardiovascular investigation of the Danish general population (n  9,149, 22-year follow-up)
and assessed the risk of ischemic cardiovascular disease in heterozygotes or homozygotes
versus noncarriers.
RESULTS Of the participants, 70.0%, 27.3%, and 2.7% were noncarriers, heterozygotes, or homozy-
gotes, respectively. Incidence of ischemic cardiovascular disease was 167 and 103 per 10,000
person-years in homozygous and noncarrier men (log-rank: p  0.006), whereas this
difference was not observed in women (p  0.33) (genotypegender interaction: p  0.03). In
homozygous versus noncarrier men 40 years of age, 40 to 50 years, and 50 years at entry,
age-adjusted relative risks (RRs) of ischemic cardiovascular disease were 3.6 (1.4 to 9.0), 2.4
(1.3 to 4.6), and 1.0 (0.6 to 1.8), respectively (agegenotype interaction in men: p  0.04);
equivalent multifactorially adjusted RRs were 3.0 (1.1 to 8.0), 2.0 (1.0 to 3.9), and 1.0 (0.6
to 1.8), respectively. The corresponding age-adjusted RR values of MI in men were 5.2 (1.5
to 18), 3.5 (1.6 to 7.5), and 0.5 (0.1 to 1.5), respectively (agegenotype interaction in men: p
 0.002); equivalent multifactorially adjusted RRs were 3.8 (1.0 to 15), 3.1 (1.4 to 6.9), and
0.5 (0.2 to 1.5), respectively.
CONCLUSIONS PlA2/PlA2 homozygosity is associated with a three-fold and four-fold risk of ischemic
cardiovascular disease and MI in young men. (J Am Coll Cardiol 2003;42:661–7) © 2003
by the American College of Cardiology Foundation
Binding of adhesive plasmaproteins as von Willebrand
factor and fibrinogen to membrane-bound glycoprotein
(GP) IIb/IIIa of platelets plays a pivotal role in platelet
aggregation (1). The PlA1/PlA2 polymorphism, also called
HPA-1a/HPA-1b or Zw(a)/Zw(b), causes a substitution of
the wild-type Leu-33 to proline in the 3-subunit of GP
IIb/IIIa, resulting in an extracellularly positioned conforma-
tional change of the 3-subunit. Therefore, it has been
considered biologically plausible to suggest an impact of
Leu33Pro on platelet aggregation (2), and consequently on
risk of ischemic cardiovascular disease (3).
In a recent meta-analysis (4) of mainly case-control
studies with conflicting results encompassing more than
17,000 individuals, aggregated results showed an odds ratio
for ischemic cardiovascular disease in PlA1/PlA2 heterozy-
gotes combined with PlA2/PlA2 homozygotes versus PlA1/
PlA1 noncarriers of 1.10 (95% confidence interval [CI] 1.03
to 1.18). Only two prospective studies have been published
so far (5,6), and all studies published have been too small to
specifically investigate homozygosity, let alone having been
stratified for age and gender.
We tested the hypothesis that platelet GP IIb/IIIa
homozygotes or heterozygotes versus noncarriers have in-
creased risk of ischemic cardiovascular disease and myocar-
dial infarction (MI), overall or stratified for age and gender.
For this purpose we used the Copenhagen City Heart
Study, a prospective cardiovascular study of the Danish
general population with 9,149 participants and a total of 22
years’ follow-up.
METHODS
From the Danish general population, by use of the Danish
Central Population Register number, we randomly recruited
4,082 men and 5,067 women who participated in the third
examination of the Copenhagen City Heart Study, 1991 to
1994 (7–12). Participants were screened for manifestations
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of ischemic cardiovascular disease (MI, non-MI ischemic
heart disease, or ischemic stroke) by a questionnaire during
1976 to 1978, 1981 to 1983, and 1991 to 1994, and by
reviewing all 1976 to 1998 hospital admissions and diag-
noses entered in the Danish National Hospital Discharge
Register (13), all 1991 to 1998 causes of deaths entered in
the Danish National Register of Causes of Death, and
medical records from hospitals and general practitioners.
Myocardial infarction was classified according to World
Health Organization International Classification of Dis-
eases 8th ed. (ICD-8) code 410, or 10th ed. (ICD-10) codes
I21-I22. Non-MI ischemic heart disease was ICD-8 codes
411-413 or ICD-10 codes I20 and I25: diagnosis was based
on characteristic symptoms of stable angina pectoris accord-
ing to the guidelines of the European Society of Cardiology
(location, character, and duration of pain and the relation of
pain to exercise [14]).
Ischemic stroke was ICD-8 codes 432-434 or ICD-10
code I63, excluding computed tomography proven hema-
toma, subarachnoidal hemorrhage, or transient ischemic
attack. Individual diagnoses were verified by experienced
cardiologists and neurologists, respectively (15). Participants
with disease before study entry were excluded from the
study (n  93).
We had 99.97% follow-up; three individuals were lost.
More than 99% were whites of Danish descent. All partic-
ipants gave written informed consent. The ethical commit-
tees of Copenhagen and Frederiksberg approved the study
(No. 100.2039/91).
The PlA2-allele, also called HPA-1b or Zw(b), is caused
by a T3C substitution in nucleotide 176 after A in the
start-codon in the gene integrin 3 (GenBank AccNo
NM_000212). This polymorphism was examined as earlier
described (16): in short, a 268-bp polymerase chain
reaction-fragment covering the whole of exon 3 (GenBank
AccNo M32672) was amplified from genomic deoxyribo-
nucleic acid by the use of intronic primers: sense: TTCT-
GATTGCTGGACTTCTCTT; antisense: TCTCTCC-
CCACGGCAAAGAGT. After thermocycling, the
polymerase chain reaction was digested with the restriction
endonuclease MspI, run on a 3% agarose gel and visualized
using ethidium bromide. The PlA1/PlA1 noncarrier geno-
type produced a 221/38/8-bp-pattern, PlA1/PlA2 heterozy-
gous genotype a 221/177/44/38/8-bp-pattern, and PlA2/
PlA2 homozygous genotype a 177/44/38/8-bp-pattern.
Blood samples were drawn in the nonfasting state.
Colorimetric and turbidimetric assays were used to measure
plasma levels of total cholesterol, high-density lipoprotein
cholesterol, triglycerides, fibrinogen (all Boehringer Mann-
heim, Mannheim, Germany), and lipoprotein(a) total mass
(DAKO A/S, Glostrup, Denmark). The diagnosis of dia-
betes mellitus was assigned according to participants’ own
knowledge of their disease status. The status of smoker was
assigned to current and former smokers.
The statistical software package SPSS (SPSS for Win-
dows, release 10.0.7, SPSS Inc., Chicago, Illinois) was used.
A p value 0.05 on a two-sided test was considered
significant. For characteristics of participants, we used the
Student t test on untransformed or log-transformed vari-
ables, Mann-Whitney U test, or the Pearson chi-square test.
Multifactorial adjustment included all other parameters
listed in Table 1 in an analysis of covariance or logistic
regression model. Continuous variables were divided in
gender-specific tertiles. It was decided a priori to stratify
main analyses for gender and age. We plotted cumulative
disease incidence against follow-up time using the Kaplan-
Meier method, and we tested differences between genotypes
using log-rank statistics. Visual inspection of log-minus-log
curves was employed to exclude disproportion of hazards over
time. Relative risk for disease with 95% CI was calculated using
the Cox regression, unadjusted, adjusted for age at entry in
decades, or all the factors listed in Table 1 (multifactorial
adjustment). We tested for multiplicative interactions among
gender, age, and genotype-status in predicting disease, by
introducing two-factor interaction terms after inclusion of
individual parent terms in the Cox regression model.
RESULTS
We genotyped 9,149 participants from the Danish general
population. Of those, 70.0%, 27.3%, and 2.7% were PlA1/
PlA1 noncarriers, PlA1/PlA2 heterozygotes, and PlA2/PlA2
homozygotes, respectively. This distribution did not differ
from Hardy-Weinberg equilibrium (chi-square test: all, p
0.81; men, p  0.97; women, p  0.77; Table 2). Allele
frequencies of the PlA1-allele and PlA2-allele were 83.6/
16.4% overall, 83.6/16.4% in men, and 83.7/16.3% in
women. Established risk factors for ischemic cardiovascular
disease, except for fibrinogen in men, diabetes and hyper-
tension in women, and lipoprotein(a) in both genders, were
evenly distributed among the three genotypes (Table 1).
Most of these differences were likely due to chance, and
none would remain significant after correction for multiple
comparison. In contrast, many differences existed in risk
factor distribution between men and women (Table 1).
Incidence of ischemic cardiovascular disease in homozy-
gous and noncarrier men was 167 and 103 per 10,000
person-years (log-rank: p  0.006) (Fig. 1, Table 2). In an
age-adjusted Cox regression model, RR of ischemic cardio-
vascular disease in homozygotes versus noncarriers was 1.5
(95% CI 1.1 to 2.2) and 0.7 (95% CI 0.4 to 1.4) in men and
women, respectively (Table 2). In accordance with this
gender difference, gender and (homozygous vs. noncarrier)
genotype interacted on ischemic cardiovascular disease (p 
Abbreviations and Acronyms
CI  confidence interval
GP  glycoprotein
ICD  International Classification of Diseases
MI  myocardial infarction
RR  relative risk
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0.03). For the end point of MI, the results were similar to
those for ischemic cardiovascular disease; however, statisti-
cal significance was not reached (Table 2). Heterozygotes
did not differ from noncarriers with respect to incidence or
risk of ischemic cardiovascular disease or MI in either gender
(Table 2). Unadjusted and multifactorial adjusted models gave
results similar to age-adjusted models (Table 2).
In homozygous versus noncarrier men aged40 years, 40
to 50 years, and 50 years at entry, age-adjusted RR values
of ischemic cardiovascular disease were 3.6 (1.4 to 9.0), 2.4
(1.3 to 4.6), and 1.0 (0.6 to 1.8), respectively (genotypeage
interaction in men: p  0.04; Table 3); equivalent multi-
factorially adjusted RR values were 3.0 (1.1 to 8.0), 2.0 (1.0
to 3.9), and 1.0 (0.6 to 1.8), respectively. The corresponding
age-adjusted RRs of MI in men were 5.2 (1.5 to 18), 3.5
(1.6 to 7.5), and 0.5 (0.1 to 1.5), respectively (agegenotype
interaction in men: p  0.002); equivalent multifactorially
adjusted RRs were 3.8 (1.0 to 15), 3.1 (1.4 to 6.9), and 0.5
(0.2 to 1.5), respectively. In women, homozygosity versus
noncarrier status did not predict ischemic cardiovascular
disease or MI in either age group (Table 3). Likewise,
heterozygosity versus noncarrier status did not predict either
end point in either age group in men or women. Unadjusted
and multifactorial adjusted models gave results similar to
age-adjusted models (Table 3).
Fibrinogen, a well-recognized predictor of MI (17,18)
directly interacting with platelet GP IIb/IIIa in aggregation
of platelets, is in our study higher among PlA2/PlA2 men
than among PlA1/PlA2 heterozygous or PlA1/PlA1 noncarrier
men (Table 1). Accordingly, fibrinogen level could con-
found the association between disease and homozygosity in
men; however, after multifactorial adjustment (including
fibrinogen), the RR for homozygous men remained elevated
(Tables 2 and 3).
Age at first MI was 61  2.5 years (mean  SE) and 66
 0.5 years in homozygous and noncarrier men (Table 4;
Mann Whitney U test: p  0.03); equivalent values for
ischemic cardiovascular disease were 64  2.0 and 67  0.5
years (p  0.07). This difference was not observed between
homozygotes and noncarrier women, or between heterozy-
gotes and noncarriers of either gender (Table 4).
The unadjusted RRs of death due to MI with seven years
of follow-up (1991 to 1994 through 1998) for noncarriers,
heterozygotes, and homozygotes were 1.0, 0.8 (95% CI 0.5
to 1.3), and 1.8 (95% CI 0.7 to 5.0) for men and 1.0, 1.0
(95% CI 0.5 to 2.2), and 1.1 (95% CI 0.2 to 8.4) for women,
Table 1. Characteristics of Participants
Noncarriers (PlA1/PlA1) Heterozygotes (PlA1/PlA2) Homozygotes (PlA2/PlA2)
Men
No. (%) 2,854 (68.7) 1,118 (28.6) 110 (2.6)
Age at entry (yrs) 44.5  0.21 44.7  0.35 45.5  1.08
Fibrinogen (mg/l) 3.06  0.02 3.07  0.03 3.33  0.11*§
Body mass index (kg/m2) 26.1  0.07 26.2  0.12 26.3  0.40
Cholesterol (mmol/l) 6.0  0.02 5.9  0.04 6.0  0.11
HDL cholesterol (mmol/l) 1.38  0.01 1.37  0.01 1.40  0.04
Lipoprotein(a) (mg/l) 297  7 278  10*‡ 273  30
Triglycerides (mmol/l) 2.1  0.04 2.2  0.08 2.1  0.13
Smoking (%) 82.2 81.3 85.5
Antihypertensive medication (%) 10.3 10.1 10.0
Cholesterol-lowering medication (%) 0.9 1.3 2.8
Diabetes mellitus (%) 4.5 4.3 4.5
p Values
vs. Men
p Values
vs. Men
p Values
vs. Men
Women
No. (%) 3,550 (70.1) 0.90 1,379 (27.2) 0.87 138 (2.7) 0.93
Age at entry (yrs) 45.8  0.20 0.000 46.0  0.31 0.001 46.2  0.89 0.64
Fibrinogen (mg/l) 3.11  0.02 0.004 3.15  0.02 0.01 3.09  0.08 0.11
Body mass index (kg/m2) 25.1  0.08 0.000 25.2  0.13 0.000 25.7  0.47 0.05
Cholesterol (mmol/l) 6.3  0.02 0.000 6.3  0.04 0.000 6.2  0.11 0.11
HDL cholesterol (mmol/l) 1.73  0.01 0.000 1.72  0.01 0.000 1.78  0.05 0.000
Lipoprotein(a) (mg/l) 322  7 0.001 334  11‡ 0.000 268  28 0.95
Triglycerides (mmol/l) 1.7  0.02 0.000 1.7  0.03 0.000 1.6  0.07 0.30
Smoking (%) 68.3 0.005 70.3 0.000 65.0 0.000
Antihypertensive medication (%) 10.3 0.99 10.1 0.98 17.4†‡ 0.10
Cholesterol-lowering medication (%) 0.5 0.13 1.3† 0.96 1.5 0.80
Diabetes mellitus (%) 2.4 0.000 2.1 0.002 5.1* 0.85
Values are means  SE or frequencies. Heterozygotes and homozygotes were compared with noncarriers of the same gender using the Mann-Whitney U test, the Pearson
chi-square test, or Student t test on untransformed or log-transformed parameters. *p 0.05. †p 0.01. Equivalent multifactorial adjusted comparison including all other covariants
listed in the Table using analysis of covariance or logistic regression: ‡p  0.05. §p  0.01. Women and men were compared using the Mann-Whitney U test, the Pearson chi-square
test, or Student t test on untransformed or log-transformed parameters.
HDL  high-density lipoprotein.
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Table 2. Incidence and Relative Risk of Ischemic Cardiovascular Disease and Myocardial Infarction in PlA1/PlA2 Heterozygotes or PlA2/PlA2 Homozygotes Versus PlA1/PlA1
Noncarriers by Cox Regression Analysis
Participants
(n)
Hardy-
Weinberg
Equilibrium
Ischemic Cardiovascular Disease Myocardial Infarction
First
Events
(n)
Incidence
(95% CI)/10,000
Person-Years
Relative Risk (95% CI)
Adjustment First
Events
(n)
Incidence
(95% CI)/10,000
Person-Years
Relative Risk (95% CI)
Adjustment
None Age Multifactorial None Age Multifactorial
Men
Noncarriers 2,854 470 103 (95–114) 1.0 1.0 1.0 215 43 (38–49) 1.0 1.0 1.0
Heterozygotes 1,118 p  0.97 190 107 (93–124) 1.1 (0.9–1.2) 1.1 (0.9–1.3) 1.0 (0.9–1.2) 88 45 (36–56) 1.1 (0.8–1.4) 1.1 (0.8–1.4) 1.0 (0.8–1.4)
Homozygotes 110 29 167 (112–239) 1.7 (1.2–2.4) 1.5 (1.1–2.2) 1.5 (1.0–2.1) 13 67 (36–115) 1.6 (0.9–2.7) 1.4 (0.8–2.5) 1.4 (0.8–2.5)
Women
Noncarriers 3,550 347 58 (52–65) 1.0 1.0 1.0 117 18 (15–22) 1.0 1.0 1.0
Heterozygotes 1,379 p  0.77 139 58 (49–69) 1.0 (0.8–1.2) 1.0 (0.8–1.2) 0.9 (0.8–1.2) 45 17 (13–23) 1.0 (0.7–1.3) 0.9 (0.7–1.3) 0.8 (0.6–1.2)
Homozygotes 138 10 43 (21–79) 0.7 (0.4–1.4) 0.7 (0.4–1.4) 0.6 (0.3–1.2) 3 12 (2–35) 0.7 (0.2–2.1) 0.7 (0.2–2.0) 0.6 (0.2–2.0)
Gendergenotype interaction test
Heterozygotes vs. noncarriers p  0.62 p  0.59 p  0.67 p  0.65 p  0.59 p  0.39
Homozygotes vs. noncarriers p  0.02 p  0.03 p  0.02 p  0.16 p  0.20 p  0.17
Multifactorial adjustment included all factors listed in Table 1.
CI  confidence interval.
}
}
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Table 3. Incidence and Relative Risk of Ischemic Cardiovascular Disease and Myocardial Infarction in PlA1/PlA2 Heterozygotes or PlA2/PlA2 Homozygotes Versus PlA1/PlA1
Noncarriers by Cox Regression, Stratified by Age
Participants
(n)
Hardy-
Weinberg
Equilibrium
Ischemic Cardiovascular Disease Myocardial Infarction
First
Events
(n)
Incidence
(95% CI)/
10,000
Person-Years
Relative Risk (95% CI)
Adjustment First
Events
(n)
Incidence
(95% CI)/
10,000
Person-Years
Relative Risk (95% CI)
Adjustment
None Age Multifactorial None Age Multifactorial
Men
40 yrs Noncarriers 999 41 28 (21–39) 1.0 1.0 1.0 17 11 (6–18) 1.0 1.0 1.0
Heterozygotes 414 p  0.45 20 33 (20–50) 1.2 (0.7–2.0) 1.2 (0.7–2.0) 1.1 (0.6–1.9) 6 9 (3–20) 0.8 (0.3–2.1) 0.8 (0.3–2.1) 0.8 (0.3–2.2)
Homozygotes 37 5 102 (33–238) 3.7 (1.5–9.4) 3.6 (1.4–9.0) 3.0 (1.1–8.0) 3 56 (12–164) 5.4 (1.6–19) 5.2 (1.5–18) 3.8 (1.0–15)
40–50 yrs Noncarriers 917 137 93 (78–109) 1.0 1.0 1.0 66 41 (32–52) 1.0 1.0 1.0
Heterozygotes 319 p  0.72 44 89 (67–122) 1.0 (0.7–1.4) 1.0 (0.7–1.4) 1.0 (0.7–1.4) 23 43 (27–65) 1.1 (0.7–1.7) 1.1 (0.7–1.7) 1.1 (0.7–1.8)
Homozygotes 30 10 210 (101–386) 2.4 (1.3–4.6) 2.4 (1.3–4.6) 2.0 (1.0–3.9) 7 136 (55–280) 3.5 (1.6–7.5) 3.5 (1.6–7.5) 3.2 (1.4–7.1)
50 yrs Noncarriers 938 292 176 (158–199) 1.0 1.0 1.0 132 72 (60–86) 1.0 1.0 1.0
Heterozygotes 385 p  0.65 126 187 (156–222) 1.0 (0.9–1.3) 1.1 (0.9–1.3) 1.0 (0.8–1.3) 59 79 (60–101) 1.1 (0.8–1.5) 1.1 (0.8–1.5) 1.1 (0.8–1.5)
Homozygotes 43 14 181 (99–304) 1.0 (0.6–1.8) 1.0 (0.6–1.8) 1.0 (0.6–1.8) 3 34 (69–98) 0.5 (0.1–1.4) 0.5 (0.1–1.5) 0.5 (0.2–1.5)
Women
40 yrs Noncarriers 1,123 19 12 (8–19) 1.0 1.0 1.0 6 3 (1–7) 1.0 1.0 1.0
Heterozygotes 409 p  0.61 10 16 (8–30) 1.4 (0.6–3.0) 1.4 (0.7–3.0) 1.1 (0.5–2.5) 5 8 (2–18) 2.2 (0.7–7.1) 2.2 (0.7–7.2) 1.3 (0.1–4.5)
Homozygotes 41 0 0 (0–70) No cases 0 0 (0–66) No cases
40–50 yrs Noncarriers 1,036 72 42 (33–53) 1.0 1.0 1.0 24 13 (8–19) 1.0 1.0 1.0
Heterozygotes 399 p  0.54 32 47 (32–66) 1.1 (0.7–1.6) 1.1 (0.7–1.6) 0.9 (0.6–1.4) 8 11 (5–22) 0.8 (0.4–1.8) 0.8 (0.4–1.8) 0.5 (0.2–1.4)
Homozygotes 43 2 26 (3–95) 0.6 (0.2–2.6) 0.6 (0.2–2.6) 0.6 (0.1–2.3) 2 25 (3–90) 1.9 (0.5–8.1) 1.9 (0.5–8.1) 2.4 (0.5–11)
50 yrs Noncarriers 1,391 256 96 (86–108) 1.0 1.0 1.0 87 30 (24–37) 1.0 1.0 1.0
Heterozygotes 571 p  0.61 97 88 (73–109) 0.9 (0.7–1.1) 0.9 (0.7–1.1) 0.9 (0.7–1.2) 32 27 (18–38) 0.9 (0.6–1.3) 0.9 (0.6–1.3) 0.9 (0.6–1.3)
Homozygotes 54 8 76 (33–150) 0.8 (0.4–1.5) 0.8 (0.4–1.6) 0.7 (0.3–1.4) 1 9 (0–50) 0.3 (0.04–2.1) 0.3 (0.04–2.1) 0.3 (0.04–2.1)
Agegenotype
interaction test
Men Heterozygotes vs.
noncarriers
p  0.85 p  0.87 p  0.93 p  0.84 p  0.84 p  0.79
Homozygotes vs.
noncarriers
p  0.03 p  0.04 p  0.08 p  0.002 p  0.002 p  0.004
Women Heterozygotes vs.
noncarriers
p  0.47 p  0.47 p  0.89 p  0.37 p  0.37 p  0.58
Homozygotes vs.
noncarriers
p  0.64 p  0.60 p  0.64 p  0.26 p  0.26 p  0.20
Multifactorial adjustment included all factors listed in Table 1.
CI  confidence interval.
}
}
}
}
}
}
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platelet GP IIb/IIIa PlA2/PlA2 compared to noncarrier
PlA1/PlA1 young men over 22 years of follow-up in a large
Danish cohort.
The more than 30 case-control studies published about
this polymorphism and risk of ischemic cardiovascular
disease reach divergent results (3,4). Two factors complicate
a direct comparison of our results with the findings of
others. Most importantly, the majority of previous studies
combine PlA1/PlA2 heterozygotes and PlA2/PlA2 homozy-
gotes versus PlA1/PlA1 noncarriers in their calculations in
order to obtain sufficient statistical power, and thus do not
study homozygotes alone. Second, most previous studies did
not investigate associations stratified on gender or age,
which proved essential in our work. Our study suggests an
association between homozygosity and ischemic cardiovas-
cular disease in men, but not in women. This association is
most pronounced in men 40 years of age, an age group
where very few women are affected. Among the group 40 to
50 years of age, we do find cases among women and also an
elevated relative risk for ischemic cardiovascular disease in
homozygous men, but not in homozygous women, thus
supporting the gender-specific association.
Contrary to most other reports, we do not find any
increased risk of ischemic cardiovascular disease among
PlA1/PlA2 heterozygotes versus PlA1/PlA1 noncarriers. Sev-
eral factors could contribute to this discrepancy: publication
bias toward positive results in small studies (4), different
ethnicity between studies, differences in study design, and
chance alone. Our study is the largest so far and, together
with the two other published prospective studies (5,6), agree
that PlA1/PlA2 heterozygosity does not increase the risk of
ischemic cardiovascular disease.
Of the many in vitro studies examining the impact of the
PlA2-allele on platelet function, two (19,20) investigated all
three genotypes separately. In these studies, PlA2 was
associated with increased platelet aggregability, and thus the
propensity to initiate thrombus formation, in a gene-dose
dependent manner. Biologically, the observation of in-
creased risk of ischemic cardiovascular disease in PlA2/PlA2
homozygotes therefore seems reasonable. However, this
remains an untested correlation that may or may not explain
the enhanced risk of homozygotes reported in our study.
Interestingly, when exposed to physiologic concentrations
of estrogen, the aggregability of PlA1/PlA2 heterozygous
platelets was inhibited more than PlA1/PlA1 noncarrier
platelets (21). This accords with our data, which demon-
strate an association between PlA2/PlA2 homozygosity and
ischemic cardiovascular disease in men only.
Prothrombotic conditions like increased platelet aggrega-
bility is believed by some investigators (22,23) to outweigh
the importance of atherosclerosis in premature MI, mainly
because of their findings of fewer stenoses on coronary
angiography in young patients when compared with old
patients with MI. Therefore, having the above-mentioned
in vitro studies on PlA-genotype and platelet aggregability in
mind (19–21,24), our finding of age-dependency in men of
the effect of the PlA2/PlA2-genotype on MI could simply be
caused by increased platelet aggregability induced by the
PlA2/PlA2-genotype operating at an early age.
In a series of autopsy studies on men, Mikkelsson et al.
(25–28) reported lower incidence of atherosclerotic lesions
but higher incidence of coronary thrombosis among PlA2-
carriers than among PlA1/PlA1 noncarriers for participants
60 years, but not for those 60 years. Although the
stratification on genotype and age in these studies (age
under or above 60 years, genotype noncarriers vs. heterozy-
gotes, and homozygotes combined) differs from our work,
those studies nevertheless support our finding of higher risk
of disease among younger homozygous men. Unfortunately,
no data on the extent of atherosclerosis (including results
from coronary angiographies) of the participants of our
study are available. Therefore, we do not know whether the
young homozygous men in our study have more or less
atherosclerosis than expected.
We cannot totally exclude that our findings represent
chance findings simply because no other studies have
demonstrated this association in young men. However, the
association was found in those 40 years old and in 40- to
50-year-old men, and the association decreased stepwise
with increasing age.
Another potential limitation of our study is that partici-
pants underwent genotyping only if they attended the 1991
to 1994 third examination. The absence of a correlation
between PlA2/PlA2 homozygosity and ischemic heart disease
in older men could be the result of a dropout of homozygous
men at an early age because of premature death or disability.
However, the stable Hardy-Weinberg equilibria throughout
the age groups (Table 3) do not support such a hypothesis.
Furthermore, age percentiles for noncarrier and homozy-
gous men display a linear relationship, as would be expected
with no selection against homozygotes (data not shown).
Thus, we do not consider selection bias against homozy-
gotes very likely, but if this does apply for our study, it
would rather result in a conservative estimate concerning
association of the PlA2-genotype with ischemic cardiovas-
cular disease, and thus cannot explain our results.
Table 4. Age at First Event in PlA1/PlA2 Heterozygotes,
PlA2/PlA2 Homozygotes, and PlA1/PlA1 Noncarriers
Ischemic Cardiovascular
Disease
Myocardial
Infarction
Age at First
Event (yrs)
p
Value
Age at First
Event (yrs)
p
Value
Men
Noncarriers 67  0.5 — 66  0.5 —
Heterozygotes 66  1.0 0.66 67  1.0 0.83
Homozygotes 64  2.0 0.07 61  2.5 0.03
Women
Noncarriers 71  0.5 — 70  1.0 —
Heterozygotes 71  1.0 0.72 69  1.5 0.80
Homozygotes 74  2.5 0.47 66  0.5 0.34
Age shown as mean  SE. The p values are by Mann-Whitney U test versus
noncarriers.
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Systematic misclassification of genotypes in this study is
unlikely, because of agreement with the Hardy-Weinberg
equilibrium and because the PCR assay included a restric-
tion enzyme site in each person assayed. Misclassification of
ischemic cardiovascular disease in the Copenhagen City
Heart Study is very low, as we have 99.97% follow-up, and
because all hospital admissions as well as deaths are regis-
tered systematically throughout Denmark.
Medication given to prevent ischemic cardiovascular dis-
ease and MI might overcome an underlying genetic risk.
Therefore, another limitation of the present study is that we
do not have complete information on all preventive medi-
cation given to all participants during the entire 22-year
follow-up; however, addition of the use of antihypertensive
and cholesterol-lowering medications at the 1991 to 1994
examination to the multifactorially adjusted models only
resulted in trivial changes in the RR estimates.
Finally, the main finding of our prospective study in the
Copenhagen City Heart Study, with a total follow-up of
163,987 person-years, is the three-fold and four-fold 22-
year risk of ischemic cardiovascular disease and MI in men
40 years homozygous for platelet GP IIb/IIIa PlA2/PlA2.
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